Navigation Links
Ampio Pharmaceuticals Receives Notice of Allowance of its Two Patent Applications on the Combination of Zertane™ with Erectile Dysfunction Drugs in Canada
Date:9/28/2011

is the most common form of male sexual dysfunction (four times the number with ED) with an estimated 23% of males suffering from this condition. The impact on the quality of life for these men and their partners can be profound. Behavioral therapy is the current standard of care for treatment of PE.

About Ampio

Ampio Pharmaceuticals, Inc. develops innovative proprietary drugs for metabolic disease, eye disease, kidney disease, inflammation, CNS disease, and male sexual dysfunction. The product pipeline includes new uses for previously approved drugs and new molecular entities ("NMEs"). By concentrating on development of new uses for previously approved drugs, approval timelines, costs and risk of clinical failure are reduced because these drugs have strong potential to be safe and effective while their shorter development times can significantly increase near term value. A key strategy includes actively exploring partnership, licensing and other collaboration opportunities to maximize Ampio's product development programs. For more information about Ampio, please visit our website, www.ampiopharma.com.

Forward-Looking Statements

Ampio's statements in this press release that are not historical fact and that relate to future plans or events are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by use of words such as "believe," "expect," "plan," "anticipate," and similar expressions. These forward-looking statements include risks associated with clinical trials, expected results, regulatory approvals, future intellectual property rights, successful commercialization and marketing of Zertane™ and combination drugs, succe
'/>"/>

SOURCE Ampio Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Ampio Announces Positive Results From 12-Week Open Label Extension Study of Zertane™ in Patients With Premature Ejaculation.
2. Champions Oncology Reports Fiscal 2012 First Quarter Financial Results
3. Ampio Pharmaceuticals Executes License and Development Agreement with Daewoong Co. Ltd. to Commercialize Zertane™ in South Korea
4. Ampio Pharmaceuticals Announces Treatment of First Patient in Phase 1b Ampion-In -Knee (AIK) Trial for Osteoarthritis in Australia
5. Ampio Pharmaceuticals, Inc. Releases Results From Phase III Clinical Trial of Zertane™ for the Treatment of Premature Ejaculation (PE), the Most Prevalent Form of Male Sexual Dysfunction
6. Ampio Pharmaceuticals Set to Join Russell 3000 Index
7. Ampio Pharmaceuticals, Inc. Appoints New Independent Director
8. Ampio Pharmaceuticals, Inc. to Begin Trading on the NASDAQ Capital Market
9. Ampio Pharmaceuticals, Inc. Receives Approval to List on the NASDAQ Capital Market
10. Five Californians Selected as Breakaway from Cancer® Champions to be Honored During Amgen Tour of California
11. Champions Biotechnology Exercises Option to License Proprietary Compound Based on Successful Tumorgraft™ Test Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... 2015 Gem Pharmaceuticals announced today that the initial ... the Company,s Phase 2 clinical trial.  This open-label study ... compound, GPX-150 (an investigational medication), in approximately 30 adults ... Logo - http://photos.prnewswire.com/prnh/20150123/170966LOGO ...
(Date:1/22/2015)... a privately held medical device company, announced today that ... ITOCHU Corporation (Tokyo Stock Exchange TYO: 8001) to sell ... cancer in Japan . ViewRay,s technology, ... only MRI-guided radiation therapy system that images and treats ...
(Date:1/22/2015)... Jan. 22, 2015  ResMed Inc. (NYSE: RMD ) ... Revenue for the quarter was $423.0 million, a 10 percent ... 14 percent increase on a constant currency basis). Net income ... the quarter ended December 31, 2013. Diluted earnings per share ...
Breaking Medicine Technology:Gem Pharmaceuticals Announces Enrollment of Initial Patients in its Phase 2 Clinical Trial to Assess the Efficacy and Safety of GPX-150 in Sarcoma Patients 2ITOCHU Named the Exclusive Distributor for ViewRay's MRI-Guided Radiation Therapy System in Japan 2ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 2ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 3ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 4ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 5ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 6ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 7ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 8ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 9ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 10ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 11
... London, UK, June 11, 2007-ReGen is pleased to ... on Colostrinin, its,nutraceutical product which the Company believes ... presented today at the,2007 International Congress on Natural ... Kruzel, ReGen's Chief,Scientific Officer. , The conference, which ...
... Norway, 11 June 2007 - Clavis Pharma (OSE: ... clinical Phase I/II,study with ELACYT in hematologic cancers ... the European Hematology Association (EHA) in,Vienna. ELACYT is ... of hematologic cancers as well as for solid ...
Cached Medicine Technology:Data Showing that ReGen's Colostrinin Supports Healthy Cognitive,Function Presented at the 2007 International Congress on Natural,Medicine in Australia 2Clavis Pharma Presented Preliminary Clinical Data on Elacyt at EHA 2
(Date:1/22/2015)... (PRWEB) January 22, 2015 The federal court ... the U.S. District Court, Southern District of West Virginia has ... in that proceeding’s first bellwether trial. In an Order dated ... new trial after finding that C.R. Bard had not proven ...
(Date:1/22/2015)... Thousand of GranuFlo lawsuits ( http://www.granuflolawsuit2014.com/ ... GranuFlo and NaturaLyte dialysis concentrates continue to move forward ... Court, District of Massachusetts, Bernstein Liebhard LLP reports. According ... remanded a case filed by the state of Louisiana ...
(Date:1/22/2015)... released a new blog post presenting the basic features of ... an accidental death and dismemberment rider for a car insurance ... benefits if the insured dies in an accident. Accidental death ... insurance. , AD&D is not expensive and can be ...
(Date:1/22/2015)... Yesterday, Senator Holly Mitchell (D-Los ... Olsen (R-Modesto) were honored by the California Healthcare ... biomedical science, medical device and pharmaceutical innovation in ... “2014 Life Sciences Champion” award from CHI President ...
(Date:1/22/2015)... years since the release of their debut recording Love is King, ... & Matthew Love – the duo are pleased to announce their ... Swan Records on February 24, 2015. , THE ROAD offers the ... all of us to walk out of the mire of our ...
Breaking Medicine News(10 mins):Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 3Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 4Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 2Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 3Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 4Health News:Accidental Death and Dismemberment Insurance Can Be Purchased at Low Prices Online 2Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 2Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 3Health News:THE ROAD by Avasa & Matthew Love -- A New Album 2Health News:THE ROAD by Avasa & Matthew Love -- A New Album 3Health News:THE ROAD by Avasa & Matthew Love -- A New Album 4
... VIEW, Calif., March 4 Based on ... biotechnology market, Frost & Sullivan presents OVATION ... Frost & Sullivan Award for Entrepreneurial Company ... company,s success in achieving its growth objectives ...
... 4 Cardiogenesis Corporation (Pink Sheets: CGCP), announced that ... and full year ended December 31, 2008 prior to ... company also said that President Richard P. Lanigan and ... Abbott will host an investor conference call that day ...
... NVC-422 Demonstrates Ability to Treat Subcutaneous InfectionsEMERYVILLE, Calif., ... NBY), a clinical stage biopharmaceutical company, today announced ... lead molecule in NovaBay,s, proprietary Aganocide(R) class of ... of Dermatology (AAD) 67th Annual Meeting in San ...
... ,Smart, house for people with dementia are just ... on 4th March, organised by the Engineering and ... is a free event aiming to bring together, ... business people. The event includes a dynamic, interactive ...
... Long Looked For Ways To Whiten Teeth In The Comfort Of Their Own ... As In The Dentist Office. A New Teeth Whitening Product, Hollywood Sexy Smile, ... Same Results Without The Costs and Hassles Of Going To The Dentist Office. ... ...
... drugs and endocrine-disrupting compounds found in our public drinking water are ... report by the Water Research Foundation, the nation,s leading drinking water ... ... 2009 -- The concentrations of pharmaceutical drugs and endocrine-disrupting compounds found ...
Cached Medicine News:Health News:Frost & Sullivan Lauds OVATION Pharmaceuticals for Its Business Model and Ability to Sustain Growth 2Health News:Frost & Sullivan Lauds OVATION Pharmaceuticals for Its Business Model and Ability to Sustain Growth 3Health News:Frost & Sullivan Lauds OVATION Pharmaceuticals for Its Business Model and Ability to Sustain Growth 4Health News:Cardiogenesis Corporation to Report 2008 Fourth Quarter and Year-End Results on March 31st 2Health News:NovaBay Pharmaceuticals Announces New Preclinical Data to be Presented at the American Academy of Dermatology (AAD) 67th Annual Meeting 2Health News:NovaBay Pharmaceuticals Announces New Preclinical Data to be Presented at the American Academy of Dermatology (AAD) 67th Annual Meeting 3Health News:Daisyphone, virtual cocoon and smart house at London science conference 2Health News:Teeth Whitening Ranks Most Desired Cosmetic Procedure For Women. Hollywood Sexy Smile Whitens Teeth At Home 8 Shades Without The Dentist. 2Health News:Levels of Trace Pharmaceuticals in Drinking Water Too Low to Impact Human Health According to Water Research Foundation Study 2Health News:Levels of Trace Pharmaceuticals in Drinking Water Too Low to Impact Human Health According to Water Research Foundation Study 3Health News:Levels of Trace Pharmaceuticals in Drinking Water Too Low to Impact Human Health According to Water Research Foundation Study 4
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: